Standardized incidence ratio was 3.0 during first year of follow-up after VTE and decreased to 1.5 during subsequent years<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Jan. 24, 2022 (HealthDay News) — For patients with psoriasis, the risk for cancer is increased at the time of or after venous thromboembolism (VTE), according to a research letter published online Jan. 18 in the British Journal of Dermatology<\/em>.<\/p>\n Sissel T. S \u00b8rensen, from Aarhus University Hospital in Denmark, and colleagues compared the observed cancer incidence among patients with psoriasis and VTE to the expected incidence using Danish national cancer rates.<\/p>\n The researchers identified 887 patients with VTE and a psoriasis diagnosis. Seventy-nine percent of the patients were older than 50 years, and 22 percent had a provoking factor (pregnancy, trauma\/fracture, or surgery) within three months before diagnosis of VTE. During the study period, 145 cancers were observed. The absolute risk for overall cancer was 4.7 percent during the first year of follow-up, corresponding to a standardized incidence ratio (SIR) of 3.0. During the subsequent years of follow-up, the overall SIR decreased to 1.5. The associations were strongest for lung cancer, colorectal cancers, and non-Hodgkin lymphoma.<\/p>\n “At the time of VTE or in the first year afterwards, we found a clearly increased cancer risk in patients with psoriasis,” the authors write. “Comprehensive research has shown that extensive screening for occult cancer in patients with VTE in general will lead to a higher rate of cancer detection, but these strategies have not been associated with improved cancer related mortality.”<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n